Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 3Terminated 2Active not recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Sarcoma 8Carcinoma, Renal Cell 7Carcinoma, Non-Small-Cell Lung 6Breast Neoplasms 5Neoplasm Metastasis 4Pancreatic Neoplasms 3Ovarian Neoplasms 3Small Cell Lung Carcinoma 2Neurofibrosarcoma 2Lung Neoplasms 2Leiomyosarcoma 2Histiocytoma, Malignant Fibrous 2Dermatofibrosarcoma 2Breast Neoplasms, Male 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Unspecified Adult Solid Tumor - Protocol Specific 1Stomach Neoplasms 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Prostatic Neoplasms 1Pheochromocytoma 1Paraganglioma, Extra-Adrenal 1Paraganglioma 1Osteosarcoma 1Melanoma 1Liver Neoplasms 1Kidney Neoplasms 1Hypertension 1Histiocytoma 1

Interventions

pazopanib 2Trabectedin 2Doxorubicin 2sapanisertib 1rucaparib 1pembrolizumab 1itacitinib 1baricitinib 1avelumab 1Vorinostat 1TTI-621 1PTC596 1Letrozole 1Ifosfamide 1INCB039110 1Docetaxel 1Dacarbazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Leiomyosarcoma × pazopanib × Clear all
NCT02601209 2022-08-23

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma

National Cancer Institute (NCI)

Phase 1/2 Terminated
151 enrolled 22 charts
Sarcoma

Leiomyosarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT01418001 2018-01-11

Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)

Memorial Sloan Kettering Cancer Center

Phase 1/2 Terminated
5 enrolled 6 charts
Sarcoma

Leiomyosarcoma, Sarcoma, Neurofibrosarcoma, Histiocytoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡